Efficacy and safety of insulin aspart biosimilar SAR341402 versus originator insulin aspart in people with diabetes treated for 26 weeks with multiple daily injections in combination with insulin glargine: A randomized, open-label trial (GEMELLI 1).
This study compared the efficacy, safety, and immunogenicity of insulin aspart biosimilar/follow-on biologic product SAR341402 (SAR-Asp) with originator insulin aspart-NovoLog®/NovoRapid® (NN-Asp) in people with type 1 diabetes (T1D) or type 2 diabetes (T2D) ) treated with multiple daily injections in combination with insulin glargine (Lantus®; Gla-100). This 6-month, randomized, open-label, phase 3 study (NCT03211858) enrolled 597 people with T1D (n=497) or T2D (n=100). Participants were randomized 1:1 to mealtime SAR-Asp (n=301) or NN-Asp (n=296) in combination with Gla-100. The primary objective was to demonstrate non-inferiority (by 0.3% margin in the intent-to-treat population) of SAR-Asp vs. NN-Asp in HbA1c change from baseline to week 26. Immunogenicity was also assessed in terms of anti-insulin aspart antibody (AIA) status (positive/negative) and titers during the study. HbA1c was similarly improved in both treatment groups (SAR-Asp -0.38%; NN-Asp -0.30%); the least squares mean difference at week 26 for SAR-Asp minus NN-Asp was -0.08% (95% confidence interval: -0.192 to 0.039), thus meeting the criteria for non-inferiority between SAR-Asp and NN-Asp and inverse non-inferiority of NN-Asp versus SAR-Asp. Changes in fasting plasma glucose and seven-point self-monitored plasma glucose profile, including postprandial glucose excursions, and insulin dosages were similar in both groups at week 26. Safety and tolerability, including AIA responses (incidence, prevalence), hypoglycemia, adverse events (including hypersensitivity events and injection site reactions), were similar between groups. SAR-Asp demonstrated effective glycemic control with a similar safety and immunogenicity profile to NN-Asp in people with diabetes treated for 26 weeks.